{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:01:32Z","timestamp":1772733692705,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.intimp.2021.108012","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T18:16:10Z","timestamp":1627668970000},"page":"108012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+\u00a0lung cancer in the kidney transplant recipient"],"prefix":"10.1016","volume":"99","author":[{"given":"Ondrej","family":"Bilek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos","family":"Holanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Jurica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Stepankova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Vasina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iveta","family":"Selingerova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandr","family":"Poprach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Borilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kazda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Zdrazilova-Dubska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.intimp.2021.108012_b0005","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2021.108012_b0010","unstructured":"http:\/\/www.transplant-observatory.org\/download\/2017-activity-data-report\/."},{"issue":"7","key":"10.1016\/j.intimp.2021.108012_b0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015677","article-title":"Cancer in the Transplant Recipient","volume":"3","author":"Chapman","year":"2013","journal-title":"Cold Spring Harb. Perspect Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.108012_b0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.trre.2012.07.001","article-title":"New concepts and best practices for management of pre- and post-transplantation cancer","volume":"26","author":"Campistol","year":"2012","journal-title":"Transplant Rev. (Orlando)"},{"issue":"9","key":"10.1016\/j.intimp.2021.108012_b0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrneph.2010.102","article-title":"Malignancy after renal transplantation: the role of immunosuppression","volume":"6","author":"In\u00e9s","year":"2010","journal-title":"Nat. Rev. Nephrol."},{"issue":"9103","key":"10.1016\/j.intimp.2021.108012_b0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2021.108012_b0035","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2165\/00003495-200767080-00006","article-title":"Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients","volume":"67","author":"Gutierrez-Dalmau","year":"2007","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.intimp.2021.108012_b0040","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1097\/JTO.0b013e3181f19226","article-title":"Characteristics of thoracic malignancies that occur after solid-organ transplantation","volume":"5","author":"G\u00e9n\u00e9b\u00e8s","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2021.108012_b0045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-08-1757","article-title":"Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy","volume":"15","author":"Kancha","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"7153","key":"10.1016\/j.intimp.2021.108012_b0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2021.108012_b0055","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0b013e31826baf83","article-title":"Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer","volume":"7","author":"Chin","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108012_b0060","first-page":"78","article-title":"Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy","volume":"29","author":"B\u00edlek","year":"2016","journal-title":"Klin. Onkol."},{"issue":"11","key":"10.1016\/j.intimp.2021.108012_b0065","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2021.108012_b0070","first-page":"493","article-title":"Cyclosporine in transplantation - a history of converging timelines","volume":"25","author":"Colombo","year":"2011","journal-title":"J. Biol. Regul. Homeost. Agents."},{"key":"10.1016\/j.intimp.2021.108012_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"A. Ann. N Y Acad. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2021.108012_b0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0270-9295(03)00090-1","article-title":"Cyclosporine nephrotoxicity","volume":"23","author":"Burdmann","year":"2003","journal-title":"Semin. Nephrol."},{"issue":"5","key":"10.1016\/j.intimp.2021.108012_b0085","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/00007890-198705000-00016","article-title":"The role of cyclosporine dosage and plasma levels in efficacy and toxicity in bone marrow transplant recipients","volume":"43","author":"Lindholm","year":"1987","journal-title":"Transplantation"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2021.108012_b0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0169-409X(97)00043-4","article-title":"Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery","volume":"27","author":"Hebert","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2021.108012_b0095","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/dmd.111.043018","article-title":"Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro","volume":"40","author":"Amundsen","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.intimp.2021.108012_b0100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2013.08.007","article-title":"Drug interactions with solid tumour-targeted therapies","volume":"89","author":"Thomas-Schoemann","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.intimp.2021.108012_b0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2021.108012_b0110","unstructured":"Modr\u00e1 kniha \u010cOS 2021. Accessed April 15, 2021. https:\/\/www.linkos.cz\/files\/modra-kniha\/20.pdf."},{"issue":"5","key":"10.1016\/j.intimp.2021.108012_b0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1258\/000456302320314430","article-title":"Cyclosporin: revisions in monitoring guidelines and review of current analytical methods","volume":"39","author":"Andrews","year":"2002","journal-title":"Ann. Clin. Biochem."},{"issue":"9","key":"10.1016\/j.intimp.2021.108012_b0120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2021.108012_b0125","doi-asserted-by":"crossref","unstructured":"T. Kokuhu, K. Fukushima, H. Ushigome et.al. Dose Adjustment Strategy of Cyclosporine A in Renal Transplant Patients: Evaluation of Anthropometric Parameters for Dose Adjustment and C0 vs. C2 Monitoring in Japan, 2001-2010. Int J Med Sci. 10 (12) (2013) 1665-1673. doi:10.7150\/ijms.6727.","DOI":"10.7150\/ijms.6727"},{"issue":"2","key":"10.1016\/j.intimp.2021.108012_b0130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/TP.0b013e3181c42b95","article-title":"Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study","volume":"89","author":"Potena","year":"2010","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.intimp.2021.108012_b0135","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/00498254.2016.1261308","article-title":"Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib","volume":"47","author":"Sekiguchi","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.intimp.2021.108012_b0140","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xalkori-epar-product-information_en.pdf."},{"key":"10.1016\/j.intimp.2021.108012_b0145","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alecensa-epar-product-information_en.pdf."},{"issue":"23","key":"10.1016\/j.intimp.2021.108012_b0150","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1158\/1078-0432.CCR-16-0536","article-title":"Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer","volume":"22","author":"Wang","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2021.108012_b0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/00498254.2016.1179821","article-title":"Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects","volume":"47","author":"Morcos","year":"2017","journal-title":"Xenobiotica"},{"issue":"17","key":"10.1016\/j.intimp.2021.108012_b0160","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases","volume":"3","author":"Costa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2021.108012_b0165","first-page":"1023","article-title":"Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases","volume":"74","author":"Kodama","year":"2014","journal-title":"CancerChemother Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108012_b0170","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/cpt.956","article-title":"Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development","volume":"104","author":"Cleary","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2021.108012_b0175","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/cpdd.298","article-title":"Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"3","key":"10.1016\/j.intimp.2021.108012_b0180","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/cancers12030526","article-title":"Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials","volume":"12","author":"Hoang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.intimp.2021.108012_b0185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2021.108012_b0190","unstructured":"NSCLC blocs version 4\/2021. National Comprehensive Cancer Network (NCCN). Accessed 21 May, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl_blocks.pdf."},{"key":"10.1016\/j.intimp.2021.108012_b0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ebiom.2019.03.019","article-title":"Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+\/calcineurin\/Erk pathway","volume":"42","author":"Liu","year":"2019","journal-title":"EBioMedicine"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921006482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:14:43Z","timestamp":1730837683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921006482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":39,"alternative-id":["S1567576921006482"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108012","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+\u00a0lung cancer in the kidney transplant recipient","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108012"}}